Abstract

The Leukemia/Lymphoma-BMT (LL-BMT) Program is an interdisciplinary program with 37 members from nine departments with over $3.5 million in annual direct research support. The chief scientific aims of the Program are: to devise novel treatments for leukemia, lymphoma and related hematologic disorders using immunotherapeutic approaches with or without concurrent stem cell transplant; to understand the immunobiology of allogeneic BMT in order to reduce its toxicity and increase its; and to understand hematopoietic stem cell biology with the ultimate goal of stem cell gene modification for therapeutic purposes. This program was recently organized to integrate more fully research activities related to clinical therapies of malignant hematologic diseases. This integration is exemplified by numerous intra-programmatic conferences, tumor boards and clinical research projects incorporating multiple disciplines.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-15
Application #
6597032
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-06-01
Project End
2003-05-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
Indirect Cost

  Institution

Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109

  Publications

Mendiratta-Lala, Mishal; Masch, William; Shankar, Prasad R et al. (2018) MR Imaging Evaluation of Hepatocellular Carcinoma Treated with Stereotactic Body Radiation Therapy (SBRT): Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys :
Kim, Yeung-Hyen; Zhu, Lingqiao; Pyaram, Kalyani et al. (2018) PLZF-expressing CD4 T cells show the characteristics of terminally differentiated effector memory CD4 T cells in humans. Eur J Immunol 48:1255-1257
Davis, Elizabeth J; Griffith, Kent A; Kim, Edward J et al. (2018) A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. Am J Clin Oncol 41:128-132
Rosselli-Murai, Luciana K; Yates, Joel A; Yoshida, Sei et al. (2018) Loss of PTEN promotes formation of signaling-capable clathrin-coated pits. J Cell Sci 131:
Tamura, Shuzo; Wang, Yin; Veeneman, Brendan et al. (2018) Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer. Bladder Cancer 4:77-90
Mendiratta-Lala, Mishal; Gu, Everett; Owen, Dawn et al. (2018) Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 102:1063-1069
Cilliers, Cornelius; Menezes, Bruna; Nessler, Ian et al. (2018) Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival. Cancer Res 78:758-768
Lorenz, Daniel A; Vander Roest, Steve; Larsen, Martha J et al. (2018) Development and Implementation of an HTS-Compatible Assay for the Discovery of Selective Small-Molecule Ligands for Pre-microRNAs. SLAS Discov 23:47-54
Zhou, Bing; Hu, Jiantao; Xu, Fuming et al. (2018) Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem 61:462-481
Chockley, Peter J; Chen, Jun; Chen, Guoan et al. (2018) Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J Clin Invest 128:1384-1396

Showing the most recent 10 out of 1493 publications